비정형 항정신병 약물로 치료받는 정신분열병 환자에서 혈당, 지질수치, 몸무게의 변화

Changes in Glucose, Lipid Levels and Body Weight in Patients with Schizophrenia Treated with Atypical Antipsychotics

The purpose of this study is to assess the effect of risperidone, olanzapine, quetiapine, amisulpride on glucose, lipid levels and body weight changes in Korean patients with schizophrenia during 12 weeks’ clinical trial. Method：The subjects were assigned to each medication group by clinical judgment of the psychiatrist. 77 subjects provided blood samples at baseline and at least at one point after medication. Planned assessment included fasting glucose and lipid levels (cholesterol, TG, HDL, LDL), body weight which were collected at baseline and at 2, 7 and 12 weeks after medication. In risperidone group, there were 22, 20, 8 and 10 subjects at baseline, 2, 7 and 12 week point. In olanzapine group, there were 23, 18, 8 and 8 subjects at each point. In quetiapine group, there were 16, 12, 8 and 6 subjects at each point. In amisulpride group, there were 16, 15, 14 and 12 subjects at each point. Result：There were increase in body weight in quetiapine, olanzapine groups. Body mass index before amisulpiride medication had correlation with weight change during 12 weeks medication. There were no significant increase in glucose level in all medication groups. There were no significant change in TG, HDL level in all medication groups. There were significant elevation in cholesterol, LDL level in Amisulpride group, but in other medication groups there were no significant increase in cholesterol, LDL level. Conclusion：Some medication induced increase in body weight, cholesterol, TG. atypical antipsychotics have potential to induce metabolic syndrome such as DM, hyperlipidemia, therefore regular examinations for early detection of metabolic side effects are necessary.